Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

amicus pharma doo podgorica - paklitaksel - prašak za suspenziju za infuziju - 100mg

Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"novartis pharma services ag" dio stranog druŠtva podgorica - dabrafenib - kapsula, tvrda - 75mg

Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"novartis pharma services ag" dio stranog druŠtva podgorica - dabrafenib - kapsula, tvrda - 50mg

Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"novartis pharma services ag" dio stranog druŠtva podgorica - dabrafenib - kapsula, tvrda - 75mg

Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - ivabradin - film tableta - 7.5mg

Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - ivabradin - film tableta - 5mg

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - agalzidaza beta - prašak za koncentrat za otopinu za infuziju - 35 mg/1 viala - 1 bočica sa praškom za koncentrat za otopinu za infuziju sadrži: 35 mg agalzidaza beta

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1)orpatients s brzo razvija težak relapsing ublažavanje multiplom sklerozom određuje se 2 ili više teških recidiva u roku od jedne godine, s 1 ili više gadolinij revitalizacije lezija na mr mozga ili značajno povećanje opterećenja t2 lezija u odnosu na najnoviji mri.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europska Unija - hrvatski - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).